IN FOCUS BIOTECH GROWTH TRUST

We made a 300pc return on this company, which has developed a breast cancer drug, in our last financial year. Gilead Sciences, the pharmaceutical company, bought Immunomedics in October last year. Historically takeovers have been a driver of biotech returns and we have been happy to see that merger activity didn’t diminish during the pandemic.